Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • lethalfang
    Member
    • Aug 2011
    • 95

    #1

    A few basic questions about mitochondrial DNA resequencing

    Hi guys,

    I've a few questions about looking for mutations in human mitochondrial DNA.

    1) Since there are only 17 kbp of DNA in the mitochondria, if I can purify mitochondrial DNA, get rid of the nuclear DNA, I don't need any capture kits to sequence mitochondrial DNA. Is that correct?

    2) Are there any companies that make primers/oligos that target mitochondrial genes? For instance, Agilent HaloPlex does not.

    3) Is it possible to capture some genes using the typical "Oncogene Panel" or a customized panel, and then combine with the whole mitochondrial DNA as in "Step 1," and sequence the combined customized nuclear gene and mitochondrial DNA?

    The answers should be the same for both MiSeq and Ion Torrent, correct?

    Thanks in advance.
  • ngseq
    Member
    • Mar 2010
    • 19

    #2
    1. In theory, you can. But it may be a problem to isolate mtDNA with sufficient amount or purity for library prep in practice. It seems that most labs use long range PCR.

    2. I don't know the answer. But I guess you can certainly design your own primers using primer3. Just be aware of nuclear mitochondrial pseudogenes when doing so.

    3. I think you can combine the two as long as you can figure out the correct ratio as this is going to determine the relative coverage between them.

    Comment

    • csquared
      Member
      • May 2008
      • 67

      #3
      The PCR primers used by Affymetrix to amplify the mtDNA in two overlapping fragments for use on their sequencing array work great for amplification prior to library prep and sequencing. The fragments are a bit over 8Kb so you still need a traditional library prep but after pooling the fragments in molar equivalents, treat the samples like standard genomic DNA and everything works great.

      There are a few different ways to purify mtDNA away from nuclear, but all are pretty labor intensive compared to PCR. It is possible through if you really want to use an non-amplified approach.

      mtDNA sequences are pretty abundant and it is not unusual to see them carry through on capture experiments like exome sequencing. You could certainly intentionally capture the mtDNA with some optimization.
      HudsonAlpha Institute for Biotechnology
      http://www.hudsonalpha.org/gsl

      Comment

      Latest Articles

      Collapse

      • SEQadmin2
        Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
        by SEQadmin2


        Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

        The systematic characterization of the human proteome has
        ...
        07-20-2026, 11:48 AM
      • SEQadmin2
        Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
        by SEQadmin2



        Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
        ...
        07-09-2026, 11:10 AM
      • SEQadmin2
        Cancer Drug Resistance: The Lingering Barrier to Rising Survival
        by SEQadmin2



        Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

        There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
        07-08-2026, 05:17 AM

      ad_right_rmr

      Collapse

      News

      Collapse

      Topics Statistics Last Post
      Started by SEQadmin2, Today, 02:55 AM
      0 responses
      1 view
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-24-2026, 12:17 PM
      0 responses
      10 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-23-2026, 11:41 AM
      0 responses
      11 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-20-2026, 11:10 AM
      0 responses
      23 views
      0 reactions
      Last Post SEQadmin2  
      Working...